Gyre Therapeutics, Inc. Class of Warrant or Right, Outstanding
Gyre Therapeutics, Inc. (GYRE) had Class of Warrant or Right, Outstanding of 85 shares as of 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2021-03-04
- 2020-12-31: Class of Warrant or Right, Outstanding 85.00 shares.
- 2019-12-31: Class of Warrant or Right, Outstanding 7.86K shares.
- 2018-12-31: Class of Warrant or Right, Outstanding 10.19K shares.
- 2018-09-30: Class of Warrant or Right, Outstanding 12.04K shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2020-12-31 | 85.00 shares 10-K · filed 2021-03-04 |
| 2019-12-31 | 7.86K shares 10-K · filed 2021-03-04 |
| 2018-12-31 | 10.19K shares 10-K · filed 2021-03-04 |
| 2018-09-30 | 12.04K shares 10-Q · filed 2018-11-01 |
| 2018-06-30 | 12.04K shares 10-Q · filed 2018-08-02 |
| 2018-03-31 | 12.04K shares 10-Q · filed 2018-05-03 |
| 2017-12-31 | 1.75M shares 10-K · filed 2020-02-20 |
| 2017-09-30 | 2.05M shares 10-Q · filed 2017-11-02 |
| 2017-06-30 | 2.05M shares 10-Q · filed 2017-08-03 |
| 2016-12-31 | 12.04K shares 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |